Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo) 2022; 57(02): 267-272
DOI: 10.1055/s-0041-1741023
Artigo Original
Osteometabólicas

Histomorphometry of Bone Microarchitecture in Rats Treated with Vitamin D and Bisphosphonate in the Management of Osteoporosis

Article in several languages: português | English
José Reginaldo Alves de Queiroz Júnior 
1   Centro de Ciências Médicas, Universidade Federal de Pernambuco, Recife, PE, Brasil
,
Marina Falcão de Souza Cartaxo 
2   Laboratório de Imunopatologia Keizo Adami, Universidade Federal de Pernambuco, Recife, PE, Brasil
,
Silvania Tavares Paz 
3   Departamento de Patologia, Universidade Federal de Pernambuco, Recife, PE, Brasil
,
Fernanda das Chagas Ângelo Mendes Tenório 
4   Departamento de Histologia e Embriologia, Universidade Federal de Pernambuco, Recife, PE, Brasil
,
Ana Janaína Jeanine Martins de Lemos 
5   Centro de Ciências Biológicas e da Saúde, Departamento de Morfologia e Fisiologia Animal, Universidade Federal de Campina Grande, Campina Grande, PB, Brasil
,
Carina Scanoni Maia 
4   Departamento de Histologia e Embriologia, Universidade Federal de Pernambuco, Recife, PE, Brasil
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective To verify how the combined administration of alendronate (ALN) and vitamin D3 (VD) acts on the bone microarchitecture in rats with glucocorticoid-induced osteoporosis.

Methods The experiment used 32 90-day-old female Wistar rats weighing between 300 and 400g. The induction of osteoporosis consisted of intramuscular administration of dexamethasone at a dose of 7.5 mg/kg of body weight once a week for 5 weeks, except for the animals in the control group. The animals were separated into the following groups: G1 (control group without osteoporosis), G2 (control group with osteoporosis without treatment), G3 (group with osteoporosis treated with ALN 0.2 mg/kg), G4 (group with osteoporosis treated with VD 10,000UI/500μL), and G5 (group with osteoporosis treated with ALN + VD). The right femurs of the rats were fixed in 10% buffered formaldehyde, decalcified, and processed for inclusion in paraffin. Histological sections were stained with hematoxylin-eosin for histomorphometric analysis. Cortical thickness and medullary cavity were measured in cross-sections.

Results There was a statistical difference (p < 0.05) between groups G3 and G5 compared with the positive control group (G2), both related to the measurement of cortical thickness and to the total diameter of the bone. In the evaluation of the spinal area, only the G3 group has shown to be statistically different from the G2 group.

Conclusion Concomitant treatment with daily ALN and weekly VD is effective in preventing glucocorticoid-induced bone loss. However, there was no difference between the therapy tested and treatment with ALN alone.

Keywords

alendronate - vitamin D - menopause - femur - rats

Financial Support

The present study received no financial support from public, commercial, or not-for-profit sources.


Work developed at the Department of Histology and Embryology of the Universidade Federal de Pernambuco, Recife, PE, Brazil.




Publication History

Received: 28 May 2021

Accepted: 09 September 2021

Article published online:
11 March 2022

© 2021. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • Referências

  • 1 Radominski SC, Bernardo W, Paula AP. et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós-menopausa. Rev Bras Reumatol 2017; 57 (S 2): S452-S466
    CrossrefGoogle Scholar
  • 2 Cosman F, de Beur SJ, LeBoff MS. et al. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014; 25 (10) 2359-2381
    CrossrefPubMedGoogle Scholar
  • 3 Si L, Winzenberg TM, Chen M, Jiang Q, Palmer AJ. Residual lifetime and 10 year absolute risks of osteoporotic fractures in Chinese men and women. Curr Med Res Opin 2015; 31 (06) 1149-1156
    CrossrefPubMedGoogle Scholar
  • 4 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285 (06) 785-795
    CrossrefPubMedGoogle Scholar
  • 5 Lazaretti-Castro M, Eis SR, Marques Neto JF. A prevenção da osteoporose levada a sério: uma necessidade nacional. Arq Bras Endocrinol Metabol 2008; 52 (04) 712-713
    CrossrefPubMedGoogle Scholar
  • 6 Kocijan R, Klaushofer K, Misof BM. Osteoporosis Therapeutics 2020. Handb Exp Pharmacol 2020; 262: 397-422
    CrossrefPubMedGoogle Scholar
  • 7 Mabey T, Honsawek S. Role of Vitamin D in Osteoarthritis: Molecular, Cellular, and Clinical Perspectives. Int J Endocrinol 2015; 2015: 383918
    CrossrefPubMedGoogle Scholar
  • 8 Rosen CJ. The Epidemiology and Pathogenesis of Osteoporosis. In: Feingold KR, Anawalt B, Boyce A. et al., editors. Endotext [Internet]. South Dartmouth, MA: MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279134/
    Google Scholar
  • 9 Gameiro VS, Schott PCM. A osteoporose em fraturas proximais do fêmur: estudo histomorfométrico. Rev Bras Ortop 2006; 41 (03) 61-69
    Google Scholar
  • 10 Arlot ME, Jiang Y, Genant HK. et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008; 23 (02) 215-222
    CrossrefPubMedGoogle Scholar
  • 11 Junqueira LCU, Junqueira LMM. Técnicas básicas de citologia e histologia. São Paulo: Editora Santos; 1983
    Google Scholar
  • 12 Carvalho ACB, Henriques HN, Pantaleão JAS. et al. Histomorfometria do tecido ósseo em ratas castradas tratadas com tibolona. J Bras Patol Med Lab 2010; 46 (03) 235-243
    CrossrefGoogle Scholar
  • 13 Parfitt AM, Drezner MK, Glorieux FH. et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2 (06) 595-610
    CrossrefPubMedGoogle Scholar
  • 14 Mata PR, Martins PA, Brito LG, Ramos MMP, Santos Junior MC. Tratamento farmacológico para a osteoporose. Geriatr Gerontol Aging 2012; 6 (04) 422-431
    Google Scholar
  • 15 Radominski SC, Bernardo W, Paula AP. et al. Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Rev Bras Reumatol Engl Ed 2017; 57 (Suppl. 02) 452-466
    PubMedGoogle Scholar
  • 16 Oliveira MM, Mendonça JCG, Masocatto DS, Oliveira JM, Jardim ECG. Osteonecrose dos Maxilares Associada ao uso de Bisfosfonato. Salusvita, Bauru 2015; 34 (02) 341-352
    Google Scholar
  • 17 Vidal MA, Medina C, Torres LM. Seguridad de los bifosfonatos. Revista Soc Esp Dolor 2011; 18 (01) 43-55
    Google Scholar
  • 18 Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010; 362 (19) 1825-1827
    CrossrefPubMedGoogle Scholar
  • 19 Sutton AL, MacDonald PN. Vitamin D: more than a “bone-a-fide” hormone. Mol Endocrinol 2003; 17 (05) 777-791
    CrossrefPubMedGoogle Scholar
  • 20 Jehan F, Voloc A. Actions classiques de la vitamine D : apport de la génétique humaine et de modèles de souris génétiquement modifiées. Biol Aujourdhui 2014; 208 (01) 45-53
    CrossrefPubMedGoogle Scholar
  • 21 Khajuria DK, Razdan R, Mahapatra DR. Medicamentos para o tratamento da osteoporose: revisão. Rev Bras Reumatol 2011; 51 (04) 365-382
    CrossrefPubMedGoogle Scholar
  • 22 Harvey RA, Ferrier DR. Bioquímica ilustrada. 5ª. ed.. Porto Alegre: Artmed; 2012
    Google Scholar
  • 23 Ferreira Junior DB, Pinto AS, Del Carlo RJ. et al. Efeitos de bifosfonatos e estatinas na reparação de fraturas em tíbias de ratas com osteoporose induzida com dexametasona. Rev Cienc Farm Basica Apl 2008; 29 (02) 203-207
    Google Scholar
  • 24 Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18 (10) 1319-1328
    CrossrefPubMedGoogle Scholar
  • 25 Valente FL, Ferreira APB, Costa LD, Mouzada MJQ, Patarroyo JH, Vargas MI. Effects of chronic mild stress on parameters of bone assessment in adult male and female rats. Pesq Vet Bras 2016; 36 (01) 106-112
    CrossrefGoogle Scholar
  • 26 Aerssens J, van Audekercke R, Talalaj M, Geusens P, Bramm E, Dequeker J. Effect of 1alpha-vitamin D3 and estrogen therapy on cortical bone mechanical properties in the ovariectomized rat model. Endocrinology 1996; 137 (04) 1358-1364
    CrossrefPubMedGoogle Scholar
  • 27 Shiraishi A, Takeda S, Masaki T. et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000; 15 (04) 770-779
    CrossrefPubMedGoogle Scholar
  • 28 Nishikawa T, Ogawa S, Kogita K. et al. Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone 2000; 27 (05) 647-654
    CrossrefPubMedGoogle Scholar